Role of ranibizumab in management of macular degeneration

Singh, Rishi P.; Kaiser, Peter K.
November 2007
Indian Journal of Ophthalmology;Nov2007, Vol. 55 Issue 6, p421
Academic Journal
No abstract available.


Related Articles

  • Retinopathy. Stylianides, Amira // Diabetes Digest;2012, Vol. 11 Issue 1, p40 

    The author discusses various studies related to retinopathy. The author states that the study conducted by A. M. Shah, N. M. Bressler, and L .M. Jampol has discussed the role of laser treatment in retinal vascular disease management. Moreover, the author provides critical analysis on the studies...

  • A CLOSER LOOK AT SAFETY.  // Ophthalmology Times Europe;Nov2014 Supplement, Vol. 10, p1 

    The article offers information on the role of the anti-vascular endothelial growth factor (VEGF) agents in the fighting against various macular diseases. It mentions that the anti-VEGF therapy stops the growth of abnormal blood vessels which has revolutionized the management of retinal disease....

  • Combination Therapies For Exudative AMD. Dadgostar, Hajir; Kaser, Peter K. // Review of Ophthalmology;May2009, Vol. 16 Issue 5, p72 

    A conference paper about the use of combination approaches in the management of age-related macular degeneration is presented. It mentions the various treatments such as verteporfin photodynamic therapy and inhibitors of vascular endothelial growth factor (VEGF) like pegaptanib, ranibizumab and...

  • Avastin, Lucentis Yield Same Results.  // Review of Optometry;Oct2010, Vol. 147 Issue 10, p6 

    The article reports on the comparative efficacy of Avastin/bevacizumab and Lucentis/ranibizumab for the treatment of age-related macular degeneration.

  • Eye on Multi's. Farrar, Maureen Meyers // Joe Weider's Muscle & Fitness;Apr2002, Vol. 63 Issue 4, p42 

    Reports on the role of multivitamins in preventing the development of macular degeneration. Vitamins used in treating macular degeneration; Preventive measures for macular degeneration.

  • ARVO 2016 meeting paves path for personalized medicine.  // Ophthalmology Times;7/1/2016, Vol. 41 Issue 11, p11 

    The article discusses the highlights of the 2016 meeting of the Association for Research in Vision and Ophthalmology (ARVO). Topics covered include the use of retinal pigment epithelium (RPE) for the treatment of wet age-related macular degeneration (AMD), the therapeutic benefit of aflibercept...

  • Estimated Cases of Blindness and Visual Impairment from Neovascular Age-Related Macular Degeneration Avoided in Australia by Ranibizumab Treatment. Mitchell, Paul; Bressler, Neil; Doan, Quan V.; Dolan, Chantal; Ferreira, Alberto; Osborne, Aaron; Rochtchina, Elena; Danese, Mark; Colman, Shoshana; Wong, Tien Y. // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    Intravitreal injections of anti-vascular endothelial growth factor agents, such as ranibizumab, have significantly improved the management of neovascular age-related macular degeneration. This study used patient-level simulation modelling to estimate the number of individuals in Australia who...

  • from THEORY to THERAPY ANGIOGENESIS AND THE TREATMENT OF AMD.  // Ophthalmology Times;5/15/2007 Theory to Therapy Supp, Vol. 32, p1 

    The article presents an various studies that focus on the treatment of age-related macular degeneration. However, the anti-angiogenic mechanisms are detrimental to normal cardiovascular function in response to tissue ischemia. Some of these studies include the assessment of cardiovascular risk...

  • Bevacizumab/pegaptanib/ranibizumab.  // Reactions Weekly;8/28/2010, Issue 1316, p12 

    The article describes the cases of 19 elderly patients who developed retinal pigment epithelial (RPE) tears after receiving pegaptinib, ranibizumab or bevacizumab for macular degeneration.

  • CATT researcher offers perspective on interpreting trial results. Correa, Mark; Hasson, Matt; Mullin, David W.; Pagnani, Michelle // Ocular Surgery News;2/25/2012, Vol. 30 Issue 4, special section p10 

    The article reports on how ophthalmologists consider data derived from the Comparison of Age-Related Macular Degeneration Traetment Trials that compared ranibizumab and bevacizumab.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics